TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer)(TIGIT/3106), CF594 conjugate, 0.1mg/mL [26628-22-8]

Biotium

TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer)(TIGIT/3106), CF594 conjugate, 0.1mg/mL

9

ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

TIGIT/3106

0.1 mg/ml

Other Conjugate

TIGIT

T cell immunoreceptor with Ig and ITIM domains

T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain containing 9; V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain containing 3; V-set and transmembrane domain-containing protein 3; VSIG9; VSIG9, VSTM3; VSTM3; Washington University cell adhesion molecule; WUCAM

Mouse

IgG2b

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4 T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is a immuno-oncology target for therapy. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Animal

Human

2°C to 8°C

12352203